DiaSorin SpA
Michele Denegri graduated in Economics and Business at Turin University in 1994. After training with KPMG Consulting, he moved to New York in 1997 to work in real estate investments.
Back in Italy in 2001, he took part in the set up of "Industria e Finanza Sgr”, a private equity fund, and managed its investment business.
He held numerous executive positions in the Fund’s various holdings, notably at Digicast S.p.A., a leading digital TV broadcaster that contributed to the creation of digital television in Italy.
In 2007, he was appointed CEO at Finde S.p.A. and its associate Ip Investimenti e Partecipazioni S.p.A., an independent private finance company where he pursued his career in private equity and venture capital, funding investments with owner’s equity and focusing on the medical technologies sector (cardiovascular and orthopedic in particular).
He performed executive roles in various other holdings, including CID Implantable Devices and Corin Group Orthopedic.
Since 2013, in addition to his work in real estate, private equity, and venture capital, he has been engaged in a number of major social enterprise initiatives for a private no-profit Foundation.
He is a Member of the Board of Directors of DiaSorin S.p.A. since 2003 and Deputy Chairman since 2013.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.